Aculys Pharma

Executive Summary

Aculys Pharma is a Japanese biopharmaceutical venture dedicated to addressing the significant drug lag in neuroscience and psychiatry by licensing and developing innovative therapies already approved overseas for the Japanese market. Founded in 2021 and headquartered in Tokyo, the company has rapidly advanced to the commercial stage with its first product, Spedia® (diazepam nasal spray), receiving regulatory approval in Japan in June 2025. Aculys focuses on epilepsy and sleep-related disorders, leveraging a portfolio of differentiated assets to capture unmet medical needs in a market underserved by novel treatments. With $140 million raised to date, the company is well-positioned to execute its strategy of bridging the gap between global innovation and local patient access. Looking ahead, Aculys Pharma aims to expand its commercial footprint with the upcoming launch of Spedia® for acute seizure clusters, which represents a significant milestone in treating epilepsy in Japan. The company's pipeline also includes promising candidates for sleep disorders, targeting indications such as narcolepsy and idiopathic hypersomnia. By focusing on high-need therapeutic areas and leveraging regulatory pathways for already-approved drugs, Aculys minimizes clinical risk while offering substantial commercial upside. The company's ability to rapidly penetrate the Japanese market and potentially forge additional licensing agreements will be key drivers of its near-term growth.

Upcoming Catalysts (preview)

• H2 2026Spedia® commercial launch and initial sales in Japan90% success
• H2 2026New licensing agreement for a late-stage CNS asset60% success
• H1 2027Phase 2/3 clinical data readout for sleep disorder candidate50% success